|
The trial of sapacitabine was for int-2 or high risk MDS patients, age 60 and over, who had failed Vidaza or Dacogen. Sapacitabine appears to lengthen survival in these worst cases from the 4 to 6 month range to the 8 to 10 month range.
The trial studied three dosage schedules, finding that the best results were with 200 mg given twice daily for 7 days. Results weren't quite as good with 300 mg given once daily for 7 days or 100 mg given once daily for 5 days per week over 2 weeks.
|